Melanoma is a type of cancer that forms from melanocytes. A melanocyte is a normal cell found in the skin that produces melanin. Melanin is a black or dark brown pigment that is seen in the skin, hair, and parts of the eye.
Melanoma is the most serious form of skin cancer. Other more common, but usually less serious, types of skin cancer include basal cell carcinoma and squamous cell carcinoma.
Of the many different types of melanoma, most are seen in the skin (this also includes nail beds, soles of the feet, and scalp), but melanoma can also occur in the eye, or on mucosal surfaces which include the anal canal, rectum, and vagina.
Pigmented Lesions are skin spots that are brown or black. They are usually moles. Pigmented lesions may change in size, color or border shape. They may itch or sting. Such changes could be warning signs that melanoma may be developing.
Careful monitoring of moles and quick action when they change in a suspicious way are among the steps you and your doctor can take to prevent melanoma and its consequences.
Patients with melanoma or pigmented lesions will be cared for by the team from Penn's Melanoma Program and its Pigmented Lesion/Melanoma Practice.
Different treatments are available for those with melanoma. Some treatments are called standard. This means they are the currently used treatments. Some treatments are being tested in clinical trials. A treatment clinical trial is a study meant to help improve current treatments or obtain information on new treatments.
When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. You may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment, while others are available during or after treatment.
Treatment options vary depending on your situation including the stage of the cancer and other factors that may be present.
Talk with your team about the approach that is best for you.
Early detection and recognition of melanoma is key to improving overall survival in patients with malignant melanoma. Most patients report a preexisting mole at the site of the melanoma.
The signs of early melanoma are based on the color, shape and size of a mole.
Most melanomas are varying shades of brown, but black, blue, or pink may be found in melanomas.
In particular, a history of change in an existing mole, including change in shape, color, or surface is an important clue that a skin spot may represent melanoma.
Itching, burning, or pain in a mole should increase suspicion of melanoma although melanomas are often not associated with local discomfort.
Bleeding and ulceration are signs of a more advanced melanoma.
The A,B,C,D's for the recognition of melanoma are useful for public education and clinicians to identify pigmented lesions suspicious for melanoma:
Melanoma can occur on any part of the body. In men, melanomas are most commonly found on the trunk and in women, melanoma often develops on the arms and legs.
Diagnosis of Melanoma
Any skin lesion suspicious for melanoma should be biopsied. The proper biopsy is essential not only to establish a diagnosis but also to allow precise histological interpretation which will determine the prognosis and plan of therapy. Most clinically suspicious skin lesions are best biopsied by complete excision taking a 1-2 mm margin of normal skin.
When detected in its earliest stages, melanoma is highly curable. The average 5 year survival rate for individuals with melanoma is 89%.
A number of factors have been identified that predict the overall prognosis of melanoma.
Staging System for Melanoma
Clinical staging is based on whether the tumor has spread to lymph nodes or distant sites.
The staging system for melanoma is determined by the American Joint Committee on Cancer (AJCC), updated in 2002, it now more accurately classifies patients into groups with similar survival.
The initial evaluation of a patient with melanoma includes
Melanoma can spread by through lymph channels and through the blood stream. Any organ can be involved by metastases, but lung and the liver are the most common sites. Therefore, the following tests are also done to determine if the melanoma has metastasized:
The majority of patients who present with melanoma do not have a distant metastatic disease at presentation; therefore, x-rays (computerized tomography scans -CT scans) to search for distant metastases (spread beyond the primary site) have an extremely low yield and consequently are not indicated in patients who do not have symptoms.
More extensive staging evaluation with CT scans of the chest/abdomen/pelvis can be considered in patients with high risk disease (thick primary melanoma > 4 mm thick or in those patients who have lymph nodes involved with melanoma) where the risk of spread to distant sites is higher.
Surgical Treatment of Primary Melanoma
Once melanoma is diagnosed, the standard treatment is surgical removal.
After the initial biopsy to diagnose the melanoma, then a “wide excision” is done. The wide excision removes an area of normal tissue around the melanoma. The extent of the surgery depends upon the thickness (depth) of the melanoma.
Large surgical excisions are no longer required. Current recommendations for surgical margins are as follows:
Sentinel lymph node mapping is a new surgical technique that can identify the draining lymph node most likely to be involved with melanoma and can be considered in patients with newly diagnosed melanoma.
Sentinel lymph node mapping may be considered in patients with melanomas > 1 mm thick and who have no evidence of clinically enlarged regional lymph nodes. The purpose of this surgical procedure is to identify regional lymph nodes in which microscopic melanoma cells may be present. This procedure is done only for patients that have a significant likelihood of metastasis to lymph nodes.
Patients with melanoma < 1mm have a low likelihood of regional lymph node involvement (<5%), and thus generally, sentinel node mapping is not indicated. If the sentinel lymph node is negative for melanoma, no further lymph node surgery is required. If melanoma is detected in the sentinel lymph node, a complete lymph node dissection is recommended.
In those patients who have enlarged local lymph nodes than a complete lymph node surgery should be done to potentially cure the melanoma. A sentinel lymph node procedure would be inappropriate in patients who have clinically enlarged local lymph nodes.
Adjuvant therapy is treatment given to reduce the risk of metastasis or recurrence after surgery for melanoma clinically confined to the skin or lymph nodes.
This therapy is “adjunctive” or extra, following surgery. Patients who are at increased risk for spread of melanoma to distant sites in the body (lung, liver, brain) are those patients with deep (thick) melanomas (> 4mm thick) or those patients with local lymph node involvement. These patients have at least a 50-75% chance of dying from melanoma. Therefore, these patients are appropriate candidates for adjuvant therapy.
Current options for adjuvant therapy include interferon or participation in clinical trials with melanoma vaccines and other forms of immunotherapy alone or combined with chemotherapy.
In 1995 the FDA recommended approval for interferon-alpha 2b based on a study (E1684) conducted by the Eastern Cooperative Oncology Group (ECOG). In that study, patients with high risk melanoma (thick primary melanoma,>4mm or node positive disease, Stage III), were treated with interferon for one year or were observed without treatment.
An intensive regimen was deliberately chosen in order to deliver interferon at the maximally tolerated dose to achieve peak drugs levels. Patients were treated with an intravenous induction phase of 20 million units/m2, 5 days a week for 1 month, followed by 11 months of 10 mu/m2 given subcutaneously three days a week.
Patients who received the interferon had a small, but significant improvement in survival. This was the first melanoma adjuvant study which demonstrated an improvement in overall survival. Based upon these results, the FDA approved high dose interferon for patients with high risk melanoma.
There are side effects associated with IFN.
It is critical that patients undergoing treatment with IFN be monitored closely and that the dose of IFN is modified appropriately for toxicity.
High dose IFN is the only treatment approved by the FDA for melanoma patients who are high risk for recurrence (Adjuvant therapy).
Follow-up and Surveillance
Patients with a history of melanoma should be followed regularly for evidence of :
The most important component is the history and physical examination. The physical examination should include a thorough skin exam as the risk of second primary melanoma is increased.
At least 3% of patients will develop an additional melanoma within 3 years of diagnosis; this risk is higher in patients with atypical moles. Regional lymph nodes should be thoroughly examined, especially in those patients without prior nodal surgery. The remainder of the examination should be comprehensive, keeping in mind frequent metastases to lung, liver, and brain.
Follow up studies generally include:
The routine use of screening CT scans, MRI's, PET scans or bone scans is not justified for follow-up.
Patient education is an integral part of the management of patients with melanoma. Patients should be instructed on how to perform monthly self-skin examinations for detection of new primary melanomas and recurrent disease. They should be educated on the clinical characteristics of melanoma and the importance of safe sun strategies.
The intensity of the surveillance and the extent of the investigation are related to risk of recurrence.
The treatment of a patient with metastatic melanoma depends upon multiple factors including:
Currently, the goals of treatment are directed toward improving or reducing symptoms.
There is no evidence that treatment of metastatic melanoma has any impact on prolonging survival. Metastatic melanoma can metastasize to virtually any organ of the body. The most common site of distant metastases is the lung. The skin, liver, and brain are also common sites of metastases.
The overall survival for patients with metastatic melanoma ranges from 4.7 to 11 months, with a median survival of 8.5 months. The estimated 5 year survival rate for patients with Stage IV disease is 5%. In highly selected patients, long term survival has been reported.
The range of treatment options includes:
Single Agent Chemotherapy
Numerous chemotherapy medications have demonstrated activity in the treatment of metastatic melanoma including dacarbazine, cisplatinum and taxanes. However, no single chemotherapy has consistently shown response rates (shrinkage rate) greater than 20%.
Dacarbazine (DTIC) remains the only chemotherapeutic agent approved by the FDA for the treatment of metastatic melanoma. Clinical trials have demonstrated overall response rates of approximately 10-20 %.
Responses are not long-lasting, generally only 3 to 6 months. Long-term complete responses are seen in only 1-2 % of the patients. The most commonly used regimen of DTIC is 800-1000 mg/m2 intravenously and repeated every 3 weeks. DTIC is generally well tolerated.
The most frequent side effect is nausea and vomiting which can be severe. Mild to moderate drop in the WBC is a common side effect.
Temozolomide (Temodar) (TMZ)
Temodar is oral chemotherapy agent that is chemically converted in the body to MTIC, which is the active metabolite of DTIC. It has a wide volume of distribution, including the brain. This is an advantage because the brain is so frequently involved with melanoma metastases.
Results from recent phase II studies of Temodar in patients with metastatic melanoma show an overall response rate of 21%, including 5% complete response.
Responses in patients with brain metastases have also been reported. The results from several phase II studies suggest that temozolomide is at least as effective as DTIC in metastatic disease.
Since TMZ is administered orally it is easy to administer and it is extremely well tolerated. The standard dose is 150-200 mg/m2/d orally on days 1 to 5. Courses are repeated every 4 weeks. The major side effect is a mild to drop in WBC counts. Mild nausea and vomiting is also common, but can be readily controlled with standard anti-nausea medications. This drug has not been approved by the FDA for the treatment of melanoma. However, because of its ease of administration and lack of toxicity compared to other melanoma therapies, Temodar is frequently used as first line therapy for patients with metastatic melanoma.
A variety of combination chemotherapy regimens have produced response rates in the 30-50% range.
The Dartmouth regimen, which includes Cisplatin, DTIC, BCNU and tamoxifen (CBDT) has been one of the standard regimens for patients with Stage IV melanoma. This combination requires hospitalization, has greater side effects and recent studies show no difference in response rate or survival compared with DTIC alone. This treatment program has been routinely covered by insurance companies for the treatment of advanced melanoma. Only the DTIC in this regimen is approved by the FDA for the treatment of melanoma, the use of the other agents in this regimen is all off-label use.
Another combination chemotherapy regimen frequently used in patients with metastatic melanoma is the CVD regimen. This includes the chemotherapy drugs cisplatin, vinblastine, and DTIC. However, the regimen has not been shown to be superior to DTIC alone. Based upon these data, at the present time there in no evidence that any combination regimen is superior to single agent DTIC and overall, DTIC appears to equivalent to Temodar.
Interferon has been evaluated extensively in patients with metastatic melanoma.
A series of phase II studies have been conducted using a variety of doses and schedules. The response rates range from 10-25%. Most of the responses have been partial, with a complete response rate less than 5%.
While interferon has been approved by the FDA for the adjuvant treatment of high risk melanoma, it is designated an orphan drug by the FDA for use in combination with IL-2. Roferon (Hoffman LaRoche interferon alpha) in combination with IL-2 was designated as on orphan drug combination for the treatment of metastatic melanoma on 5/11/90.
IL-2 (aldesleukin), a potent T cell activator is approved by the FDA for the treatment of metastatic melanoma. Reponses have been reported as well as some durable complete responses in a small percentage of patients receiving IL-2. Median response duration was 8.9 months (range 1.5 months to more than 106 months). Because the adverse effects of IL-2 are frequent, often serious, and sometimes fatal, the potential benefit of the drug to the patient must be weighed carefully against the possible risks involved.
The currently approved regimen by the FDA for patients with metastatic melanoma consists of two 5 day courses of IL-2 separated by a rest period. Two high dose regimens have been used, 600,000 IU/kg or 720,000 IU/kg given q 8 h over 15 minutes for 14-15 doses per cycle. This is followed by 7-10 day rest period between the two cycles. Repeat courses can be given at 8-12 weeks if the patient is responding to treatment. Typically, 2 or 3 courses are given to patients with a good response, with a maximum of 5 courses. Other dosing regimens include continuous IV infusion or subcutaneous administration with lower doses of IL-2. Some studies report less serious side effects with these alternative methods of delivery or doses of IL-2, but it remains unclear whether there is comparable efficacy.
The most common side effects include hypotension (low blood pressure), diarrhea, kidney and breathing problems, fever, chills, and vomiting.
Because of low response rates and substantial toxicity of high dose IL-2, its use should be restricted to carefully selected patients and administered by experienced clinicians at established cancer treatment centers. Careful assessment of cardiac and pulmonary function is mandatory prior to initiation of therapy.
Treatment for In-transit metastases in Melanoma
Isolated limb perfusion (ILP) is an operation for a type of metastatic melanoma called in-transit metastases. In transit metastases is spread of melanoma along lymphatic vessels in the skin which forms nodules either in the skin or under the skin away from the primary melanoma site.
Most of the time there are too many nodules to simply remove them with surgery. This is because they will almost always come back . When this happens in an arm or leg ILP can be performed.
ILP is a surgical procedure on the blood vessels to and from the extremity. An operation is done to put tubes into the artery going into the leg and the vein leaving the leg. A machine then circulates very high doses of a chemotherapeutic drug called melphalan through the arm or leg for an hour. In this way very high doses of chemotherapy can be given to the extremity without causing other side effects. For more information on ILP visit http://www.uphs.upenn.edu/surgery/clin/eos/ILP.html.
Vaccine therapy for the treatment of melanoma is a new, promising area for the treatment of melanoma, particularly in the adjuvant setting.
There are generally two approaches currently undergoing clinical investigation, whole cell vaccines (autologous or allogeneic) and peptide-based or defined antigens. Currently, vaccine approaches should be considered experimental.
Biochemotherapy combines immunotherapy with chemotherapy and has been studied in patients with metastatic melanoma.
Multiple phase II studies demonstrated response rate of 50%, with a 10% complete response rate. The recent results of randomized phase III clinical trials comparing biochemotherapy either to IL-2 and IFN or to chemotherapy have been disappointing with no evidence to date that this very toxic therapy improves overall survival in patients with metastatic disease. This therapy is associated with significant toxicity.
Until prospective randomized clinical trials demonstrate a benefit of biochemotherapy, this approach remains investigational.
Nicholas Martell was first diagnosed with prostate cancer more than ten years ago. He was healthy for many years after being treated with radiation therapy. Nick recently experienced a recurrence of his cancer. Physicians at Penn tailored his treatment
Peter O'Dwyer, MD, professor of Hematology-Oncology and program director of Development Therapeutics in the Abramson Cancer Center, was interviewed on NBC10's 10! Show about Penn's work as part of the Stand Up to Cancer Dream Team... Read more